Mirum Pharmaceuticals
MIRM
$94.11
-11.04%
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan liver diseases, with its lead product Livmarli (maralixibat) approved for cholestatic pruritus in Alagille syndrome. The company has established itself as a niche player in the rare disease space with three approved medicines—Livmarli, Cholbam, and Ctexli—and a pipeline targeting PFIC and adult cholestatic liver diseases. Investor attention is currently centered on the company's rapid revenue growth trajectory, driven by Livmarli's commercial expansion, and the path to sustained profitability as operating losses narrow. Recent analyst upgrades and strong price momentum reflect growing confidence in Mirum's commercial execution and pipeline potential.…
MIRM
Mirum Pharmaceuticals
$94.11
Investment Opinion: Should I buy MIRM Today?
Rating: Buy. Thesis: Mirum Pharmaceuticals is a high-growth commercial-stage biotech with accelerating revenue, narrowing losses, and strong analyst support, making it an attractive investment for growth-oriented investors. The consensus rating is Strong Buy with an average target of $146.50, implying 29.6% upside.
Supporting Evidence: Revenue grew 49.8% YoY in Q4 2025 to $148.9M, gross margin is high at 80.7%, operating margin improved from -24.4% to -3.1% YoY, and free cash flow turned positive at $5.5M. The forward PS ratio of 2.29 (based on estimated revenue of $1.73B) is reasonable compared to the trailing PS of 7.61, suggesting the market expects significant growth. The stock has outperformed the S&P 500 by 100% over the past year.
Risks & Conditions: Key risks include failure to sustain 50% revenue growth, margin compression, or pipeline setbacks. This Buy would be downgraded to Hold if revenue growth decelerates below 30% or if operating losses widen. The stock appears fairly valued relative to its growth rate, with a PEG ratio of 2.25, but is not cheap on a trailing basis. Overall, Mirum is a compelling growth story with improving fundamentals.
Sign up to view all
MIRM 12-Month Price Forecast
Mirum's strong revenue growth and margin improvement support a bullish stance, but the high trailing valuation and negative net income warrant medium confidence. The base case of 40-50% growth and continued margin expansion is most likely, leading to a target in the $125-150 range. Key catalysts include upcoming earnings and pipeline data. If revenue growth accelerates or profitability is achieved earlier, the bull case becomes more probable. Conversely, a growth deceleration or clinical failure would shift the stance to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Mirum Pharmaceuticals's 12-month outlook, with a consensus price target around $146.50 and implied upside of +55.7% versus the current price.
Average Target
$146.50
0 analysts
Implied Upside
+55.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$125 - $185
Analyst target range
Mirum is covered by 14 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.31 on a 1-5 scale). The average target price is $146.50, implying approximately 29.6% upside from the current price of $113.03. The distribution leans heavily bullish, with no hold or sell ratings among the recent actions, indicating strong conviction in the company's prospects. The target price range spans from $125.00 (low) to $185.00 (high), representing a spread of $60. The high target of $185 assumes continued revenue acceleration, margin expansion, and potential pipeline catalysts, while the low target of $125 still implies 10.6% upside, suggesting downside risk is limited. Recent ratings from firms like TD Cowen, HC Wainwright, and Morgan Stanley have all been reiterated as Buy or Outperform, with no downgrades in the past six months. The wide spread between low and high targets reflects uncertainty around the pace of revenue growth and profitability, but the overall sentiment is decisively positive.
Bulls vs Bears: MIRM Investment Factors
Mirum Pharmaceuticals presents a compelling growth story with accelerating revenue, narrowing losses, and positive free cash flow inflection. The bull case is supported by strong analyst consensus and a path to profitability, while the bear case centers on negative net income, high trailing valuation, and product concentration. Currently, the bull case has stronger evidence given the rapid revenue growth and margin improvement, but the key tension is whether the company can sustain 50%+ revenue growth and achieve sustained profitability in the next 12 months. If growth decelerates or profitability disappoints, the premium valuation could compress significantly.
Bullish
- Revenue Growth Accelerating: Q4 2025 revenue of $148.9M grew 49.8% YoY, up from $99.4M in Q4 2024, demonstrating strong commercial execution for Livmarli and acquired products.
- Path to Profitability Nearing: Net loss narrowed 76% YoY from -$23.8M to -$5.7M in Q4 2025, with operating margin improving from -24.4% to -3.1%, indicating significant operating leverage.
- Positive Free Cash Flow Inflection: Free cash flow turned positive at $5.5M in Q4 2025 versus -$5.1M in Q4 2024, marking a key milestone that reduces reliance on external financing.
- Strong Analyst Conviction: 14 analysts rate the stock a Strong Buy (mean 1.31 on 1-5 scale) with an average target of $146.50, implying 29.6% upside from $113.03.
Bearish
- Negative Net Income Persists: Despite improvement, TTM net income remains negative at -$5.7M, and ROE is -7.4%, indicating the company is not yet profitable on a trailing basis.
- High Valuation on Trailing Sales: Trailing PS ratio of 7.61 is near the high end of the biotech industry average (5-8x), suggesting a premium that may not be justified if growth slows.
- Dependence on Livmarli Growth: Revenue concentration in Livmarli and rare disease markets creates single-product risk; any setback in commercial expansion or competition could materially impact results.
- Short-Term Price Pullback: Stock declined 1.69% in the past month despite strong 1-year gains, and is trading 13% below its 52-week high of $130, indicating potential profit-taking or consolidation.
MIRM Technical Analysis
Mirum's stock is in a strong uptrend, with a 1-year price change of +116.66%, significantly outperforming the S&P 500's +16.47%. The current price of $113.03 sits at 76.8% of its 52-week range ($50.25 to $130.00), indicating the stock is closer to its highs but not overextended, suggesting sustained bullish momentum with room for further upside. The stock's beta of 0.485 implies lower volatility than the market, which is unusual for a biotech but may reflect its commercial-stage stability. Over the past 3 months, the stock has gained 23.54%, while the 1-month change is -1.69%, showing a short-term pullback after a strong run. This divergence between the 1-month decline and the robust 1-year trend could signal a healthy consolidation or profit-taking within an ongoing uptrend, rather than a trend reversal. The 6-month change of +19.87% confirms the intermediate-term bullish bias. The stock is currently trading near its 52-week high of $130.00, which acts as a key resistance level. A breakout above $130 would signal a continuation of the uptrend and could open the door to further gains. On the downside, the 52-week low of $50.25 provides a distant support level, but more immediate support may be found near the $100 psychological level. With a beta of 0.485, the stock is less volatile than the market, meaning it may experience smaller drawdowns during market declines, which is favorable for risk-averse investors.
Beta
0.51
0.51x market volatility
Max Drawdown
-26.8%
Largest decline past year
52-Week Range
$55-$130
Price range past year
Annual Return
+76.3%
Cumulative gain past year
| Period | MIRM Return | S&P 500 |
|---|---|---|
| 1m | -26.7% | +2.8% |
| 3m | -12.2% | +4.2% |
| 6m | -6.3% | +11.3% |
| 1y | +76.3% | +21.5% |
| ytd | +20.6% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MIRM Fundamental Analysis
Mirum's revenue trajectory is strongly accelerating, with Q4 2025 revenue of $148.9 million representing 49.8% YoY growth, up from $99.4 million in Q4 2024. The trailing twelve-month revenue trend shows consistent sequential growth from $69.2M (Q1 2024) to $148.9M (Q4 2025), driven entirely by product sales. This robust growth is the cornerstone of the investment case, indicating successful commercial execution for Livmarli and the acquired Cholbam and Ctexli. The company is nearing profitability, with net income improving from a loss of -$23.8 million in Q4 2024 to a loss of -$5.7 million in Q4 2025, a 76% reduction in net loss. Gross margin remains high at 80.7% in Q4 2025, reflecting a favorable product mix and scale benefits. Operating margin improved from -24.4% in Q4 2024 to -3.1% in Q4 2025, demonstrating significant operating leverage as revenue grows. The company's balance sheet is solid, with $298.2 million in cash at the end of Q4 2025 and a current ratio of 2.67, indicating ample liquidity. Free cash flow turned positive at $5.5 million in Q4 2025, compared to -$5.1 million in Q4 2024, marking a key inflection point. Debt-to-equity is manageable at 1.02, and the company has no significant debt repayment obligations, reducing financial risk. ROE remains negative at -7.4% due to accumulated losses, but the trend is improving as losses narrow.
Quarterly Revenue
$148932000.0B
2025-12
Revenue YoY Growth
+49.8%
YoY Comparison
Gross Margin
81.0%
Latest Quarter
Free Cash Flow
$54873000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MIRM Overvalued?
Since Mirum has negative net income (TTM net income of -$5.7 million in Q4 2025), we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 7.61, while the forward PS ratio (based on estimated revenue of $1.73 billion) is approximately 2.29, implying the market expects significant revenue growth. The gap between trailing and forward PS suggests aggressive growth expectations are priced in. Compared to the biotechnology industry average PS ratio (typically around 5-8x for commercial-stage biotechs), Mirum's trailing PS of 7.61 is near the high end, reflecting a premium for its high growth rate. However, the forward PS of 2.29 is more reasonable, indicating that the current valuation may be justified if revenue targets are met. Historically, Mirum's PS ratio has ranged from 20x to 154x over the past five years, with the current 7.61x near the lower end of its historical range. This suggests that despite the stock's strong performance, valuation multiples have compressed as revenue has grown, potentially offering a more attractive entry point relative to history. The PB ratio of 12.6 is elevated, but this is common for biotech firms with intangible assets.
PE
-168.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
231.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Mirum's primary financial risk is its continued net losses, with TTM net income of -$5.7M and negative ROE of -7.4%. While losses are narrowing, any unexpected increase in operating expenses (R&D or SG&A) could delay profitability. The company has $298.2M in cash and a current ratio of 2.67, providing a solid liquidity buffer, but debt-to-equity of 1.02 indicates moderate leverage. Revenue concentration in Livmarli and rare disease markets means that any commercial setback or pricing pressure could significantly impact top-line growth.
Market & Competitive Risks: The stock's trailing PS ratio of 7.61 is at the high end of biotech peers, making it vulnerable to multiple compression if growth slows. With a beta of 0.485, the stock is less volatile than the market, but it is still sensitive to sector rotation and risk appetite for growth stocks. Competitive risks include potential new entrants in the IBAT inhibitor space for cholestatic pruritus, though Livmarli's approved status provides a moat. Regulatory risks are moderate as the company has three approved products, but pipeline setbacks (e.g., volixibat for adult cholestatic liver diseases) could dampen sentiment.
Worst-Case Scenario: In a severe downturn, the stock could retest its 52-week low of $50.25, representing a 55.5% decline from the current price of $113.03. This could be triggered by a significant revenue miss, clinical trial failure, or broader biotech selloff. The analyst low target of $125 provides a more moderate downside of 10.6%, but the 52-week low represents a realistic worst-case based on historical volatility and the stock's max drawdown of -20.55% over the past year.
FAQ
The key risks are: 1) Financial: Continued net losses (-$5.7M in Q4 2025) and negative ROE (-7.4%) mean the company is not yet profitable, and any cost overruns could delay profitability. 2) Competitive: Livmarli faces potential competition from other IBAT inhibitors, which could erode market share. 3) Pipeline: Failure of volixibat or other pipeline candidates could dampen long-term growth prospects. 4) Valuation: The trailing PS of 7.61 leaves the stock vulnerable to multiple compression if growth slows. The most severe risk is a 55.5% decline to the 52-week low of $50.25 if a major catalyst fails.
The 12-month forecast is based on three scenarios: Bull case (30% probability) targets $150-$185, driven by 60%+ revenue growth and profitability. Base case (50% probability) targets $125-$150, with 40-50% growth and continued margin improvement. Bear case (20% probability) targets $90-$125, with growth deceleration or setbacks. The most likely scenario is the base case, with the stock reaching the analyst average target of $146.50. Key assumptions include sustained Livmarli growth and operating leverage. The stock's strong momentum and analyst support suggest upside, but risks remain.
Mirum's trailing PS ratio of 7.61 is near the high end of the biotech industry average (5-8x), suggesting it is fairly valued to slightly overvalued on a historical basis. However, the forward PS ratio of 2.29 (based on estimated revenue of $1.73B) implies the market expects significant growth, making the stock appear undervalued relative to future revenue. Compared to its own history, the current PS is near the lower end of its 5-year range of 20x-154x, indicating multiple compression as revenue has grown. The PB ratio of 12.6 is elevated but common for biotech. Overall, the valuation is reasonable if the company meets growth expectations, but it leaves little room for error.
Mirum Pharmaceuticals offers a compelling risk/reward for growth investors, with strong revenue acceleration (49.8% YoY), narrowing losses, and a consensus Strong Buy rating with 29.6% upside to the average analyst target of $146.50. However, the stock trades at a trailing PS of 7.61, which is elevated, and the company is not yet profitable on a TTM basis. It is a good buy for investors who believe the company can sustain 40%+ revenue growth and achieve profitability within the next 12-18 months. For value-oriented investors, the high valuation and negative earnings may be a deterrent. The biggest downside risk is a growth deceleration or clinical failure, which could lead to a 10-55% decline.
Mirum is best suited for a long-term investment horizon of 2-3 years, as the company is in a growth phase with accelerating revenue and a path to profitability. The stock's beta of 0.485 indicates lower volatility than the market, making it less suitable for short-term trading. However, the 1-year price change of +116.66% shows strong momentum that could benefit short-term traders, but the recent 1-month decline of -1.69% suggests short-term uncertainty. For long-term investors, the focus should be on revenue growth and margin expansion. A minimum holding period of 12-18 months is recommended to allow the company to achieve profitability and for pipeline catalysts to materialize.